A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism
Louis, Edouard; Vermeire, S.; Rutgeerts, P.et al.
2002 • In Scandinavian Journal of Gastroenterology, 37 (7), p. 818-824
[en] Background: Two-thirds to three-fourths of patients with either refractory luminal or fistulizing Crohn disease respond to infliximab treatment. The ability or inability to respond seems to persist over time. Biological characteristics and/or genetic background can influence the response to treatment. The aim was to assess the value of C-reactive protein and TNF-alpha serum levels before treatment as well as the TNF -308 gene polymorphism in the prediction of response to infliximab treatment in Crohn disease. Methods: Two-hundred-and-twenty-six Crohn disease patients treated in the setting of an expanded access programme to infliximab in Belgium were studied. There were 136 refractory luminal diseases and 90 refractory fistulizing diseases. Luminal diseases were treated with one single infusion; fistulizing diseases with three infusions at weeks 0, 2 and 6. A clinical response to treatment was defined as either a Crohn disease activity index <150 (complete) or a drop of 70 points (partial) at week 4, for luminal disease, and as either complete fistula healing (complete) or a decrease of at least 50% of the number of draining fistulas on two consecutive visits between weeks 0 and 18, for fistulizing disease. CRP and serum TNF-α levels were measured at week 0 before treatment and were compared between responders and non- responders. Patients were genotyped for the -308 TNF gene polymorphism, and allelic as well as genotype frequencies were compared between responders and non- responders. Results: There were 73.2% responders (46.4% complete and 26.8% partial) and 26.8% non- responders. Response rates were similar in luminal and fistulizing diseases. CRP level before treatment was significantly higher in responders than in non-responders (16.8 mg/l (5-160) versus 9.6 mg/l (5-143); P = 0.02). Furthermore, response rate was significantly higher in patients with elevated CRP (> 5 mg/l) than in patients with a normal CRP value (< 5 mg/l) before treatment (76% versus 46%; P = 0.004; OR: 0.26 (0.11-0.63)). Allelic and genotype frequencies for -308 TNF gene polymorphis m were not significantly different between responders and non- responders - with the exception of a slightly higher TNF2 frequency in nonresponders in luminal disease (22.1% versus 11.6%; P = 0.04). However, this was not associated with a significant difference in genotype frequencies. Conclusion: A positive clinical response to infliximab was associated with a higher CRP level before treatment in our population of Crohn disease patients, but there was no relevant association with -308 TNF gene polymorphism. We therefore suggest that CRP level may help to identify better candidates for infliximab treatment.
Disciplines :
Rheumatology Gastroenterology & hepatology
Author, co-author :
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Vermeire, S.
Rutgeerts, P.
De Vos, M.
Van Gossum, A.
Pescatore, Pierre ; Université de Liège - ULiège > Relations académiques et scientifiques (Droit)
Fiasse, R.
Pelckmans, P.
Reynaert, H.
D'Haens, G.
Malaise, Michel ; Université de Liège - ULiège > Département des sciences cliniques > Rhumatologie
Belaiche, Jacques ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Language :
English
Title :
A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism
Targan S., Hanauer S., Van Deventer S.J.H., Mayer L., Present D.H., Braakman T. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-α for Crohn's disease. Crohn's disease cA2 Study Group. N Engl J Med 337:1029-1035.
Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., Van Hogezand R.A. (1999) Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340:1398-1405.
Van Dullemen H.M., Van Deventer S.J., Hommes D.W. (1995) Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109:129-135.
D'Haens G., Van Deventer S., Van Hogezand R. (1999) Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 116:1029-1034.
Baert F.J., D'Haens G.R., Peeters M., Hiele M.I., Schaible T.B., Shealy D. (1999) Tumor necrosis factor-α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's enterocolitis. Gastroenterology 116:22-28.
Van Deventer S.J.H. (1999) Review article: Targeting TNFα as a key cytokine in the inflammatory processes of Crohn's disease - The mechanisms of action of infliximab. Aliment Pharmacol Ther 13(SUPPL. 4):3-8.
Stevens C., Waltz G., Singaram C. (1992) Tumor necrosis factor a, interleukin-1β and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 37:818-826.
Reinecker H.C., Steffen M., Witthoeft T. (1993) Enhanced secretion of tumor necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 94:174-181.
Schreiber S., Nikolaus S., Hampe J. (1999) Tumor necrosis factor-α and interleukin 1β in relapse of Crohn's disease. Lancet 353:459-461.
Louis E., Ribbens C., Godon A., Franchimont D., De Groote D., Hardy N. (2000) Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol 120:241-246.
Pender S.L.F., Fell J.M.E., Chamow S.M., Askenazi A., McDonald T.T. (1998) A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol 160:4098-4103.
Rutgeerts P., D'Haens G., Targan S. (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remisssion in Crohn's disease. Gastroenterology 117:761-769.
Fagan E.A., Dyck R.F., Maton P.N., Hodgson H.J., Chadwick V.S., Petrie A. (1982) Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest 12:351-359.
Saverymuttu S.H., Hodgson H.J., Chadwick V.S., Pepys M.B. (1986) Differing acute phase response in Crohn's disease and ulcerative colitis. Gut 27:809-813.
Boirivant M., Leoni M., Tariciotti D., Fais S., Squencia O., Pallone F. (1988) The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol 10:401-405.
Taylor K.D., Plevy S.E., Yang H., Landers C.J., Bary M.J., Rotter J.I. (2001) ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 120:1347-1355.
Nedospasov S.A., Udalova I.A., Kuprash D.V., Tuetskaya R.L. (1991) DNA sequence polymorphism at the human tumor necrosis factor (TNF) locus. Numerous TNF/lymphotoxin alleles tagged by two closely linked microsatellites in the upstream region of the lymphotoxin gene. J Immunol 147:1053-1059.
Wilson A.G., De Vreis N., Pociot F., Di Giovine F.S., Van der Putte L.B.A., Duff G.W. (1993) An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 177:557-560.
Uglialoro A.M., Turbay D., Pesavento P.A., Delgado J.C., Mckenzie F.E., Gribbenj G. (1998) Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor alpha gene promoter. Tissue Antigen 52:456-461.
Negoro K., Kinouchi Y., Hiwatashi N., Takahashi S., Takagi S., Satoh J. (1999) Crohn's disease is associated with novel polymorphisms in the 5′-flanking region of the tumor necrosis factor gene. Gastroenterology 117:1062-1068.
Wilson A.G., Symons J.A., McDowell T.L., McDevitt H.O., Duff G.W. (1997) Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc Natl Acad Sci USA 94:3195-3199.
Bouma G., Crusius J.B.A., Oudkerk Pool M., Kolkman J.J., Von Blomberg B.M.E., Kostense P.J. (1996) Secretion of tumor necrosis factor α and lymphotoxin a in relation to polymorphism in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 43:456-463.
Louis E., Franchimont D., Piron A., Gevaert Y., Schaaf-Lafontaine N., Roland S. (1998) Tumour necrosis factor (TNF) gene polymorphism influences TNF-α production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 113:401-406.
McGuire W., Hill A.V.S., Alsopp C.E.M., Greenwood B.M., Kwiatkowski D. (1994) Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 371:508-511.
Roy S., McGuire W., Mascie-Taylor C.G.N., Saha B., Hazra S.K., Hill A.V.S. (1997) Tumor necrosis factor promoter polymorphism and susceptibility to lepromatous leprosy. J Infect Dis 176:530-532.
Conway D.J., Holland M.J., Bailey R.L., Campbell A.E., Mahdi O.S.M., Jennings R. (1997) Scarring trachoma is associated with polymorphism in the tumor necrosis factor alpha (TNF-α) gene promoter and with elevated TNF-α levels in tear fluid. Infect Immun 65:1003-1006.
Cabrera M., Shaw M.A., Sharpies C., Williams H., Castes M., Convit J. (1995) Polymorphism in tumor necrosis factor gene associated with mucocutaneous leishmaniasis. J Exp Med 182:1259-1264.
Mira J.P., Cariou A., Grall F., Delclaux C., Losser M.R., Heshmati F. (1999) Association of TNF2, a TNF-α promoter polymorphism, with septic shock susceptibility and mortality. JAMA 282:561-565.
Louis E., Peeters M., Franchimont D., Seidel L., Fontaine F., Demolin G. (2000) Tumour necrosis factor (TNF) gene polymorphism in Crohn's disease (CD); influence on disease behaviour?. Clin Exp Immunol 119:64-68.
Best W.R., Becktel J.M., Singleton J.W. (1979) Rederived values of the eight coefficients of the Crohn's disease activity index (CDAI). Gastroenterology 77:843-846.
Bunce M., Taylor C.J., Welsh K.I. (1993) Rapide HLA-DQB typing by eight PCR amplifications with sequence-specific primers (PCRSSP). Human Immunol 37:201-206.
Louis E., Satsangi J., Roussomoustakaki M., Parkes M., Fanning G., Welsh K. (1996) Cytokine gene polymorphisms in inflammatory bowel disease. Gut 39:705-710.
Louis E., Belaiche J., Van Kemseke C., Schaaf N., Mahieu P., Mary J.Y. (1995) Soluble interleukin-2 receptor in Crohn's disease. Assessment of disease activity and prediction of relapse. Dig Dis Sci 40:1750-1756.
Fiocchi C. (1998) Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology 115:182-205.
Louis E., Van Kemseke C., De Groote D., Franchimont P., Belaiche J. (1994) Il-6, TNF-α soluble TNF-α receptor serum level in Crohn's disease. Gut 35.
Beutler B., Cerami A. (1986) Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature 320:584-586.
Brinkman B.M., Zuijdeest D., Kaijzel E.L., Breesveld F.C., Verweij C.L. (1995) Relevance of the tumor necrosis factor alpha (TNF alpha)-308 promoter polymorphism in TNF alpha gene regulation. J Inflamm 46:32-41.
Westendorp R.G.J., Langermans J.A.M., Huizinga T.W.J., Vermeij C.L., Stuck A. (1997) Genetic influence on cytokine production and fatal meningococcal disease. Lancet 349:170-173.
Mascheretti S., Hampe J., Kruis W., Raedler A., Reddig J., Schreiber S. (2000) Evaluation of TNF microsatellites and SNPs in a cohort of chronic active, therapy refractory Crohn's disease patients treated with anti-TNF alpha. Gastroenterology 188.
Siegel S.A., Shealy D.J., Nakada M.T. (1995) The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 7:15-25.
Knight D.M., Trinh H., Le J. (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30:1443-1453.
Scallon B.J., Moore M.A., Trinh D.M., Ghrayeb J. (1995) Chimeric ant-TNF-α monoclonal antibody, cA2, binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 7:251-259.
Nikolaus S., Raedler A., Kühbacher T., Sfikas N., Fölsch U.R., Schreiber S. (2000) Mechanisms in failure of infliximab for Crohn's disease. Lancet 356:1475-1479.